期刊文献+

刍议药品生产企业如何报告个例药品不良反应

Discussion on How Drug Manufacturers Report Individual Case Adverse Drug Reactions
下载PDF
导出
摘要 通过系统回顾我国法律法规、ICH与ISPE相关指导原则,分析了自发报告、源于有组织数据收集系统的报告、源于文献的报告、境外发生的严重报告、合同报告以及其他来源等6种不同来源药品不良反应/事件报告,对个例报告提出了最低报告要求、报告内容与时限,对源自有组织数据收集系统的报告、境外发生的严重报告提出了具体报告要求,在汇总报告中提出了如何分析个例报告的要求,以期为国内药品生产企业按要求报告药品不良反应/事件提供参考。 This paper systematically reviewed laws and regulations in our country, relevant guidelines of ICH and ISPE, analyzed six different sources of adverse drug reactions/ adverse events, such as spontaneous reports, sourced from organized data collection scheme,literature,abroad, contractual agreements and other sources, put forward the minimum data elements, contents and time frames of individual report,specific reporting requirements of those sourced from organized data collection scheme and abroad,and put emphasis on the requirements on how to analyze individual report in summary report. It's aimed to provide reference for manufacturers according to reporting requirements.
作者 李宁 任经天
出处 《中国药物警戒》 2016年第2期80-83,共4页 Chinese Journal of Pharmacovigilance
关键词 药品生产企业 药品不良反应 不良事件 报告要求 manufacturer adverse drug reaction(ADR) adverse event reporting requirements
  • 相关文献

参考文献11

二级参考文献9

  • 1ISPE. Guidelines for Good Pharmacoepidemiology Practices (GPP). [EB/OL].2010-5-14[2011-02-01 ].http://www.pharmacoepi,org/ resources/guidelines_08027 .cfm.
  • 2FDA. Guidance for Industry Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment[EB/OL].http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4136b1_02_Good%20Pharmacovigilance%20Practices.pdf,2014.
  • 3EMEA. Guideline on good pharmacovigilance practices(GVP) Module V-Risk management systems[EB/OL].http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf,2014.
  • 4ICH. POST-APPROVAL SAFETY DATA MANAGEMENT:DEF-INITIONS AND STANDARDS FOR EXPEDITED REPORTING (ICH E2D)[EB/OL].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf,2014.
  • 5ICH. PHARMACOVIGILANCE PLANNING (ICH E2E)[EB/OL].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2E/Step4/E2E_Guideline.pdf,2014.
  • 6Brian L.Strom. Pharmacoepidemiology 4th ed[M].West Sussex,England:John Wiley and Sons,Ltd,2005.
  • 7CFDA.中药注射剂风险管理计划指导原则(试行).
  • 8Prieto L,Spooner A,Hidalgo-Simon A. Evaluation of the effectiveness of risk minimization measures[J].Pharmacoepidemiology and Drug Safety,2012,(08):896-899.
  • 9任经天,王胜锋,侯永芳,杜晓曦,李立明.常用药品不良反应信号检测方法介绍[J].中国药物警戒,2011,8(5):294-298. 被引量:72

共引文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部